Introduction

Scarlet fever, once a feared and widespread childhood illness, remains a significant public health concern despite advances in medical care. Caused by the bacterium Streptococcus pyogenes, commonly known as group A streptococcus (GAS), scarlet fever is characterized by a distinctive rash, fever, and sore throat. While its incidence declined dramatically in the 20th century due to widespread antibiotic use, recent years have seen a resurgence in several regions, particularly in East Asia, prompting renewed clinical and epidemiological interest. This article provides a detailed, evidence-based update on scarlet fever, covering its pathophysiology, clinical presentation, diagnostic approach, treatment strategies, and current epidemiological trends.

Pathophysiology and Etiology

Scarlet fever results from infection with Streptococcus pyogenes (GAS), a Gram-positive bacterium that colonizes the throat and skin. The hallmark of scarlet fever is the production of exotoxins—specifically erythrogenic toxins (erythrogenic toxin A, B, and C)—which are encoded by bacteriophages carried by certain strains of GAS. These toxins trigger an immune response that leads to the characteristic rash and systemic symptoms.

The bacteria typically enter the body via the respiratory tract, often through inhalation of respiratory droplets from an infected individual or via contact with contaminated surfaces. Once established in the throat, GAS replicates and releases toxins that cause tissue damage and stimulate the immune system, leading to the clinical features of scarlet fever.

Recent genomic studies have revealed that the resurgence of scarlet fever may be linked to the emergence of new or more virulent GAS strains, such as the M1T1 clone, which has been associated with increased toxin production and enhanced immune evasion. Additionally, environmental and socioeconomic factors, including overcrowding and limited access to healthcare, may contribute to the persistence and spread of the infection.

Clinical Presentation and Symptoms

Scarlet fever typically affects children aged 5–15 years, although it can occur in individuals of any age. The onset of illness is usually abrupt, with the following symptoms commonly observed:

1. Sore Throat (Pharyngitis): This is often the first symptom, presenting as a severe, painful sore throat with difficulty swallowing. Physical examination may reveal redness and swelling of the tonsils, often with white or yellow exudates. Swollen, tender cervical lymph nodes are frequently present.
2. Fever: High-grade fever (often >38.5°C or 101.3°F) is a hallmark of the infection and usually precedes or coincides with the rash. Chills and general malaise are common.
3. The Scarlet Fever Rash: The rash is the most distinctive feature and typically appears 12–48 hours after the onset of fever and sore throat. It begins on the face—especially around the ears and cheeks—and spreads to the trunk, extremities, and groin within 12–24 hours.
   • Appearance: The rash is bright red, raised, and has a sandpaper-like texture due to widespread erythema and fine papules.
   • Distribution: It commonly affects the neck, chest, and abdomen, with a tendency to spare the palms and soles. In severe cases, it may involve the palms and soles.
   • Palmar and Plantar Involvement: The palms and soles may show redness and peeling during the recovery phase.
   • Pastia’s Lines: In skin folds—such as the axillae, antecubital fossae, and groin—linear, dark red streaks may appear due to increased vascular congestion. This is a key diagnostic sign.
   • Duration: The rash typically lasts 5–7 days, with gradual fading and desquamation (peeling) of the skin, particularly on the palms and soles, which may persist for several weeks.
4. Strawberry Tongue: This is another hallmark sign. Initially, the tongue is coated with a white or yellow pseudomembrane due to a coating of bacteria and dead cells. After 1–2 days, the coating sloughs off, revealing a red, swollen, and bumpy surface—resembling a strawberry. This is due to the inflammation of the filiform papillae on the tongue.
5. Systemic Symptoms: Additional symptoms include headache, nausea, vomiting, abdominal pain, and general malaise. In rare cases, toxic shock-like syndrome may develop, especially in association with specific toxin-producing strains.

It is important to note that not all patients exhibit the full spectrum of symptoms. Some may present with only a sore throat and fever, while others may have a rash without severe systemic illness. The clinical presentation can vary based on the strain of GAS, the host’s immune status, and prior exposure.

Epidemiology and Emerging Trends

Historically, scarlet fever was a leading cause of childhood mortality in the 19th and early 20th centuries. The advent of penicillin in the 1940s drastically reduced its incidence and severity. However, in the 21st century, a notable resurgence has been reported, particularly in East Asia, including China, Japan, and South Korea.

A 2022 study published in The Lancet Infectious Diseases reported a 50-fold increase in scarlet fever cases in China between 2010 and 2020, with a peak incidence in 2019. Similar trends have been observed in the UK, where public health authorities reported a record number of cases in 2019–2020, with a significant increase in the 5–9 age group. The reasons for this resurgence remain under investigation but are thought to involve:

• Emergence of novel or hypervirulent GAS strains with increased toxin production.
• Changes in population immunity due to reduced exposure over decades.
• Improved surveillance and diagnostic capabilities, leading to better case detection.
• Environmental factors, such as climate change and seasonal patterns, which may influence transmission.

Interestingly, while scarlet fever is still relatively rare in North America and Western Europe, the trend in East Asia has prompted global health agencies to monitor the situation closely.

Diagnosis

Diagnosis is primarily clinical, based on the characteristic triad of sore throat, fever, and sandpaper-like rash, along with the presence of strawberry tongue and Pastia’s lines. However, confirmatory testing is essential to differentiate scarlet fever from other conditions, such as viral exanthems, measles, or drug reactions.

1. Rapid Antigen Detection Test (RADT): This is a quick, point-of-care test that detects GAS antigens in throat swabs. While highly specific (>95%), it has variable sensitivity (70–90%). False negatives may occur due to low bacterial load or improper sampling.
2. Throat Culture: This remains the gold standard for diagnosis. It involves culturing a throat swab on selective media (e.g., blood agar with bacitracin). While more sensitive than RADT, it takes 24–48 hours for results, which may delay treatment.
3. Serological Testing: Antibody tests (e.g., anti-DNase B, anti-streptolysin O) are not used for acute diagnosis but may help confirm recent GAS infection in cases of post-infectious complications like rheumatic fever.
4. PCR Testing: Polymerase chain reaction (PCR) assays offer high sensitivity and specificity and are increasingly used in clinical settings. They can detect GAS DNA within hours and are particularly useful in outbreak settings.

It is critical to emphasize that a positive test for GAS alone does not confirm scarlet fever, as asymptomatic carriage is common. Therefore, clinical judgment remains paramount. In cases of high suspicion, empirical antibiotic treatment may be initiated even before test results are available.

Treatment and Management

Prompt antibiotic therapy is essential to shorten the duration of illness, reduce transmission, and prevent complications. The following are the main treatment options:

1. First-Line Antibiotics:
   • Penicillin V (oral): 250 mg twice daily for 10 days.
   • Amoxicillin: 250 mg twice daily for 10 days; preferred in children due to better palatability.
   • Cefalexin: An alternative for patients with penicillin allergy (not severe).
2. For Penicillin-Allergic Patients:
   • Clindamycin: 300 mg twice daily for 10 days (especially effective against toxin-producing strains).
   • Azithromycin or Clarithromycin: Macrolides are alternatives but may be less effective due to increasing resistance.
3. Intravenous Therapy: Reserved for severe cases, such as sepsis, meningitis, or complications requiring hospitalization.

Duration of Therapy: A full 10-day course is recommended to ensure eradication of the bacteria and prevent complications. Premature discontinuation increases the risk of relapse and transmission.

Supportive Care:

• Analgesics: Acetaminophen or ibuprofen for fever, sore throat, and headache.
• Hydration: Encourage fluid intake to prevent dehydration.
• Rest: Adequate rest supports recovery and immune function.

Infection Control: Patients should be isolated for at least 24 hours after starting antibiotics to prevent spread. Hygiene measures—such as handwashing, covering coughs, and avoiding sharing utensils—should be emphasized.

Prognosis and Complications

With timely and appropriate antibiotic treatment, the prognosis for scarlet fever is excellent. Most patients recover fully within 2–3 weeks without long-term sequelae. Symptoms typically begin to improve within 24–48 hours of starting antibiotics, with fever and sore throat resolving within 2–3 days.

However, untreated or inadequately treated infections can lead to serious complications:

1. Rheumatic Fever: A delayed autoimmune response that may develop 2–4 weeks after the infection. It can cause carditis (heart inflammation), arthritis, chorea (involuntary movements), and subcutaneous nodules. Rheumatic heart disease, a long-term consequence, may lead to valve damage and heart failure. The incidence is low in developed countries due to effective antibiotic use but remains a concern in resource-limited settings.
2. Acute Glomerulonephritis (AGN): A post-infectious immune-mediated kidney disease that typically develops 1–3 weeks after the infection. It presents with hematuria, proteinuria, hypertension, and edema. While most cases resolve spontaneously, severe cases may require dialysis.
3. Suppurative Complications: These include peritonsillar abscess, mastoiditis, sinusitis, and pneumonia. These are more common in patients with delayed treatment.
4. Toxic Shock Syndrome: Rare but life-threatening, associated with toxin-producing strains of GAS.

Prevention and Public Health Implications

Prevention focuses on reducing transmission and early treatment. Key strategies include:

• Vaccination: While no licensed vaccine is currently available, research is ongoing. Candidate vaccines targeting the M protein or other surface antigens are in preclinical and early clinical trials.
• Hygiene Education: Promoting hand hygiene, respiratory etiquette, and avoiding close contact with infected individuals.
• Surveillance: Enhanced reporting and monitoring of cases can help detect outbreaks early.
• Antibiotic Stewardship: Ensuring appropriate use of antibiotics to reduce resistance and prevent overuse.

Conclusion

Scarlet fever, though historically considered a childhood illness of the past, is experiencing a resurgence in certain regions, underscoring the need for continued vigilance. Its hallmark rash, sore throat, and fever—along with the strawberry tongue—are distinctive clinical features that aid diagnosis. Prompt antibiotic treatment is effective and prevents serious complications such as rheumatic fever and kidney disease. As emerging strains and changing epidemiological patterns emerge, ongoing research, surveillance, and public health initiatives are essential to mitigate the impact of this bacterial infection in the 21st century.